Press Releases Press Releases Randomized Controlled Trial Confirms Impella CP® Improves Survival in Heart Attack with Cardiogenic Shock 07. Apr 2024 Learn More Analysis Showcases Potential for More Complete Revascularizations with Impella Compared to IABP during HRPCI 18. May 2023 Read More Johnson & Johnson Completes Acquisition of Abiomed 22. Dec 2022 Learn More FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial 21. Dec 2022 Read More First Patients in the World Treated with Impella RP Flex with SmartAssist 06. Dec 2022 Read More Johnson & Johnson to Acquire Abiomed 01. Nov 2022 Learn More Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure 21. Oct 2022 Read More Yale University Study Demonstrates Significant Survival Benefit in High-Risk PCI with Impella Support 13. Oct 2022 Read More Multi-Center, Multi-Society Study of Impella®-Supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77% 20. Sep 2022 Read More Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81% 19. Sep 2022 Read More Unloading with Impella® for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients 17. Sep 2022 Read More Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella 19. Aug 2022 Read More SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes 19. May 2022 Read More World’s First Patient Implanted with Impella BTR Minimally Invasive Heart Pump 26. Apr 2022 Read More First Patient in Japan Treated with Impella 5.5® with SmartAssist® 06. Apr 2022 Read More 1 2 NPS-2558
